Melatonin Boosts DNA Repair in Night Shift Workers by 80% in New Trial
A small clinical trial finds melatonin supplements significantly increased DNA repair activity in night shift workers during daytime sleep.
Summary
A new clinical trial published in Occupational & Environmental Medicine found that melatonin supplements may help night shift workers repair DNA damage caused by overnight work. Forty workers were randomly assigned to take 3mg of melatonin or a placebo daily for four weeks, consumed about an hour before daytime sleep. Researchers measured urinary levels of 8-OHdG, a biomarker reflecting oxidative DNA repair activity. Workers taking melatonin showed 80% higher 8-OHdG levels during daytime sleep compared to the placebo group, suggesting enhanced DNA repair. Night shift work is known to suppress natural melatonin production and impair the body's ability to fix oxidative DNA damage, a process linked to elevated cancer risk. Researchers caution that larger trials are needed before melatonin can be formally recommended.
Detailed Summary
Night shift work carries well-documented health risks, including elevated rates of certain cancers, metabolic disruption, and accelerated cellular aging. One key mechanism involves suppression of melatonin, the hormone that normally rises in darkness and plays a role beyond sleep regulation — it also supports the body's ability to repair oxidative DNA damage. When melatonin is chronically suppressed, DNA repair capacity may decline, allowing cellular damage to accumulate over time.
A new randomized placebo-controlled trial published in Occupational & Environmental Medicine directly tested whether supplemental melatonin could restore this repair capacity. Forty experienced night shift workers — all working at least two overnight shifts per week for six or more months — were assigned to take 3mg of melatonin or a matching placebo roughly one hour before daytime sleep, for four weeks.
The primary outcome was urinary 8-OHdG, a validated biomarker of oxidative DNA repair activity. Higher urinary excretion during sleep indicates the body is actively repairing DNA damage. Workers in the melatonin group showed 80% higher 8-OHdG levels during daytime sleep compared to the placebo group — a substantial and statistically meaningful difference suggesting meaningfully enhanced repair activity.
Interestingly, this effect was not observed during the subsequent night shift period, implying the benefit is specifically tied to sleep-phase repair processes rather than a continuous effect throughout the day. This finding aligns with melatonin's known role in supporting restorative biological functions that occur primarily during sleep.
Despite the compelling signal, important caveats apply. The trial was small, involving only 40 participants, and lasted just four weeks. The researchers explicitly caution against recommending melatonin as a cancer-prevention strategy until larger, longer-term trials confirm the results. Still, for the estimated millions of chronic night shift workers globally, these findings represent a practical, low-cost, and low-risk avenue worth monitoring as evidence develops.
Key Findings
- Melatonin (3mg daily) increased DNA repair biomarker 8-OHdG by 80% during daytime sleep in night shift workers
- DNA repair benefit appeared specifically during sleep, not during subsequent night shift hours
- Night shift work suppresses natural melatonin, potentially weakening oxidative DNA repair and raising cancer risk
- Trial was randomized and placebo-controlled, strengthening reliability despite its small size of 40 participants
- Researchers caution larger studies are needed before melatonin is recommended for cancer risk reduction
Methodology
This is a research summary reporting on a small randomized placebo-controlled clinical trial published in Occupational & Environmental Medicine, a peer-reviewed BMJ Group journal, lending solid source credibility. The study used a validated biomarker (urinary 8-OHdG) to assess DNA repair activity and included activity trackers for objective sleep measurement. With only 40 participants over four weeks, the evidence is preliminary but methodologically sound for an early-phase trial.
Study Limitations
The trial included only 40 participants over four weeks, making it insufficient to draw conclusions about long-term cancer risk or clinical outcomes. The biomarker 8-OHdG reflects repair activity but does not directly confirm reduced cancer incidence or disease prevention. Independent replication in larger, more diverse populations across longer durations is needed before formal recommendations can be made.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.